

North America SGLT2 Inhibitors Market US\$ 16.37 Billion Size Anticipated by 2034, Growing at a 8.4% Annual Rate

Growing urbanization and elevated stress way of living drive the North America SGLT2 inhibitors market

NEW YORK CITY, NY, UNITED STATES, November 26, 2024 /EINPresswire.com/ -- The North America SGLT2 inhibitors market report assesses the competitive scenario of the market, examining all the established players and new market entrants.

“

Uncomplicated approach to detrimental food and restricted possibilities for physical activities in urban ambiance push the market forward.”

Polaris Market Research

According to the report, the North America SGLT2 inhibitors market is projected to reach a size of US\$ 16.37 billion by 2034, growing at a CAGR of 8.4% from 2024 to 2034. The market is driven by the increasing prevalence of type 2 diabetes and the growing awareness of the benefits of SGLT2 inhibitors. The report also identifies the key players in the market and provides a detailed analysis of the competitive landscape.

Key findings of the report include:

Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a category of oral prescription medications that are FDA-consented for usage with diet and exercise to lessen blood sugar in grown-ups with type 2 diabetes. Some SGLT2 inhibitors are also FDA consented for usage in people with chronic kidney diseases (CKD) or heart failure to lessen the probability of heart attack involving those people who do not have diabetes.

One kind of SGLT2 inhibitor is now FDA consented to assist in enhancing blood sugar regulation in children 10 years older or even more with type 2 diabetes. Research is ongoing to observe if SGLT2 inhibitors can be of assistance for some kidney illnesses in children who do not have diabetes. The economic variation and residing conditions in urban areas cause heightened rates of obesity, hypertension, diabetes, and kidney illnesses, impacting the North America SGLT2 inhibitors market demand favorably.

For more information, please contact Polaris Market Research at info@polarismarketresearch.com.

<https://www.polarismarketresearch.com/industry-analysis/north-america-sgl2-inhibitors->

[market/request-for-sample?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01](https://www.polarismarketresearch.com/request-for-sample?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01)

□□□ □□□□□□ □□□□□□□□□□:

- The North America SGLT2 inhibitors market size was valued at USD 7.32 billion in 2024 and is projected to grow to USD 16.37 billion by 2034.
- Escalated blood sugar levels causing a surge in the acquisition of diabetes medicines fuel the need for the SGLT2 inhibitors market in North America.
- The market segmentation is primarily based on indication, drug, distribution channel, and country.

- The study provides market insights into the US and Canada.

□□□□□□□□□□ □□□□□□□□□□:

Spearheading market contenders are funding massively in research and development to augment their product lines, which will push the market growth during the forecast period. The top market participants, such as

- AstraZeneca
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Glenmark Pharmaceuticals Ltd.
- Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals, Inc.)
- Lexicon Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Sanofi
- Pfizer Inc.

□□□□□ □□ □□□□□□□□□□ □□□□□□□□□□□□ □□ □□□□□ □□□□□□□□ □□□□□□. □□□□, □□□□ □□□□□□□□ □□□□□□□□□□ □□□□□□□□□□□□ □□ □□□□□□ □□□□□□□□□□□□ □□□ □□□□□ □□□□□□□□□□□□.

□□□□ □□□ □□□□ □□ □□□ □□□□□ □□□□□□□□□□□□:



- In December 2023, Boehringer Ingelheim acquired European Commission consent for Jardiance (empagliflozin) 10mg and 25mg tablets to be utilized as a supplement to diet and exercise for the cure of deficiently regulated type 2 diabetes mellitus in children ten years or older in the European Union.
- In September 2023, Eli Lilly and Company and Boehringer Ingelheim International GmbH declared that the US FDA has consented to Jardiance (empagliflozin) for its productivity in decreasing the probability of cardiovascular death for heart failure in patients impacted by chronic kidney illnesses.

□□□□□□ □□ □ □□□□□□□ □□ □□□□ □□□□□□ □□□□□□□□:

https://www.polarismarketresearch.com/industry-analysis/north-america-sgl2-inhibitors-market/request-for-discount-pricing?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01

□□□□□□ □□□□□□ □□ □□□□□□□□□□□□:

Progressive Healthcare Framework: An excessively progressive healthcare framework that sanctions speedy and productive handling of diabetes is fueling the North America SGLT2 inhibitors market growth. The region's reach to progressive medical provision, skilled healthcare exponents and complete healthcare services ascertains that patients are armed with most current treatments involving SGLT2 inhibitors.

Rising Cases of Obesity: Obesity notably increases the probability of advancing type 2 diabetes as a result of progressive body fat, especially around the abdomen, which causes insulin aversion and provocations in controlling blood sugar levels.

Development of SGLT2 Inhibitors: Pharmaceutical firms are organizing the advancement and fostering of SGLT2 inhibitors to oblige the growing aggregate of diabetic patients, especially in the obese community.

□□□□□□□□ □□□□□□□□:

The US is anticipated to witness a significant CAGR from 2025 to 2034. The country's robust growth is due to its hosting a sizeable pharmaceutical research and developmental zone that has caused the immediate acquisition of contemporary SGLT2 inhibitors and amalgamated therapies.

Canada accounted for the largest share of North America's SGLT2 inhibitors market in 2024. This is primarily because the Canadian government, in association with territorial and local health jurisdictions, has set in motion a gamut of strategies to fight the diabetes outbreak.

□□□□□□□□ □□□□□□□□:

By Indication Outlook

- Cardiovascular
- Chronic Kidney Disease (CKD)
- Type 2 Diabetes
- Others

By Drug Outlook

- Farxiga (Dapagliflozin)
- Inpefa (Sotagliflozin)
- Invokana (Canagliflozin)
- Jardiance (Empagliflozin)
- Qtern (Dapagliflozin/Saxagliptin)
- Other SGLT2 Inhibitors

By Distribution Channel Outlook

- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies

By Country Outlook

- US
- Canada

□□□□□□ □□□□ □□□□ □□□□ □□□□□□ □□□□□□□□:

https://www.polarismarketresearch.com/industry-analysis/north-america-sgl2-inhibitors-market/inquire-before-buying?utm_source=EIN&utm_medium=EIN&utm_campaign=EIN&utm_id=01

Browse PMR's North America SGLT2 Inhibitors Market Report Coverage from Different Publications:

[□□□□□ □□□□□□□ □□□□2 □□□□□□□□□□ □□□□□□ □□□□ □□□□□□□□ □□ □□□□□ □□ 16.37 □□□□□□□ □□ 2034, □□□□□□□ □□ □□ 8.4% □□□□](#)

□□□□□□ □□□□ □□□□□□□□ □□□□□□□□:

Udder Health Market

<https://www.polarismarketresearch.com/industry-analysis/udder-health-market>

Onychomycosis Market

<https://www.polarismarketresearch.com/industry-analysis/onychomycosis-market>

DNA and Gene Cloning Services Market

<https://www.polarismarketresearch.com/industry-analysis/dna-and-gene-cloning-services->

[market](#)

Muscle Stimulator Market

<https://www.polarismarketresearch.com/industry-analysis/muscle-stimulator-market>

Platelet Rich Plasma (PRP) Market

<https://www.polarismarketresearch.com/industry-analysis/platelet-rich-plasma-market>

Polymers Polymers Polymers Polymers & Polymers, Polymers:

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

Likhil G

Polaris Market Research and Consulting

+ +1 929-297-9727

sales@polarismarketresearch.com

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/763895861>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.